APASL and AASLD Consensus Guidelines on Imaging Diagnosis of Hepatocellular Carcinoma: A Review by Tan, Cher Heng et al.
SAGE-HindawiAccess to Research
International Journal of Hepatology
Volume 2011, Article ID 519783, 11 pages
doi:10.4061/2011/519783
Review Article
APASL andAASLDConsensusGuidelines onImagingDiagnosis
ofHepatocellular Carcinoma:A Review
CherHeng Tan,1 Su-Chong Albert Low,2 andChoonHuaThng3
1Department of Diagnostic Radiology, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Singapore 308433
2Department of Diagnostic Radiology, Singapore General Hospital, Outram Road, Singapore 169608
3Department of Oncologic Imaging, National Cancer Centre, 11 Hospital Drive, Singapore 169610
Correspondence should be addressed to Cher Heng Tan, tchers1977@gmail.com
Received 14 January 2011; Accepted 15 February 2011
Academic Editor: Pierce Chow
Copyright © 2011 Cher Heng Tan et al.ThisisanopenaccessarticledistributedundertheCreative CommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Consensusguidelinesforradiologicaldiagnosisofhepatocellularcarcinoma(HCC)havebeendraftedbyseverallargeinternational
workinggroups. This article reviews the similarities and diﬀerences between the most recent guidelines proposed by the American
AssociationforStudyofLiverDiseasesandtheAsianPaciﬁcAssociationfortheStudyoftheLiver.Current evidence forthevarious
imaging modalities for diagnosis of HCC and their relevance to the consensus guidelines are reviewed.
1.Introduction
Consensus guidelines have been drafted by several large
international working groups on diﬀerent occasions in
an attempt to standardise the surveillance, diagnosis, and
management of HCC. Of the major working groups, the
European Association for the Study of the Liver was the ﬁrst
toestablish consensusguidelineson theclinicalmanagement
of HCC following the Barcelona European Association for
the Study of the Liver (EASL) Conference in 2000 [1]. The
American Association for Study of Liver Diseases (AASLD)
adapted these recommendations to issue a set of consensus
recommendations in 2005 [2]. This was more recently
updated in 2010 [3]. The Asian Paciﬁc Association for the
Study of the Liver (APASL) itself also developed a set of
consensus recommendations in December 2008 [4].
The rationale for a set of guidelines on management
of the growing problem of HCC is several fold. Firstly,
it aims to maximise healthcare resources when targeting
large populations at risk, based on current evidence-based
practice. Secondly, it allows for a standardised method
of diagnosis in the era of computed tomography (CT)
and magnetic resonance imaging (MRI). Lastly, it provides
clinicians with a guide to the treatment of HCC.
Establishing universalguidelinesforimagingdiagnosis of
HCC can be challenging, particularly in the lesions that do
not display classical imaging features. Nevertheless, imaging
diagnosis of HCC is important because it is noninvasive,
given that the incidence of needle tract tumour seeding
following biopsy of HCC is small but not negligible (overall
2.7%, or 0.9% per year) [5], while the risk of signiﬁcant
haemorrhage-related complications following image guided
liver biopsy is 0.5% (based on a retrospective review of 3636
percutaneouscore biopsiesperformed at a single institution)
[6]. Furthermore, it allows for proper delineation of extent
of disease, which impacts on the type of treatment, including
local ablative therapy, such as radiofrequency ablation,
transhepatic arterial chemo-embolisation (TACE), surgery
ortransplant. Itcanallowfor accuratelocalisationoftumour
foci,makingitpossibleforlocalablativetherapiesandproper
surgical planning.
The purpose of this paper is to review the similarities
and diﬀerences between the more recent guidelines on
radiologicaldiagnosisofHCCasproposedbytheAPASLand
the AASLD.
2.RadiologicalDiagnosisof HCC
The use of imaging in HCC diagnosis can be best divided
into two main categories. The ﬁrst is in the surveillance
of patients at high-risk for developing HCC. The second is2 International Journal of Hepatology
in the diagnosis of HCC based on an abnormal screening
test.
3.Surveillance
Prospective screening of patients at high-risk of developing
HCC increases the proportion diagnosed with potentially
curable disease. A screening strategy should focus on those
patients with chronic HBV or HCV virus infection that has
progressed tocirrhosis since more than 40%ofthesepatients
will develop HCC [7].
As for the time interval between surveillance tests, both
the AASLD and APASL recommend measurement of serum
alpha-fetoprotein (AFP) levels combined with grey-scale
ultrasound (US) of the liver for surveillance of HCC [3, 4]
at 6-monthly intervals for HBV carriers and patients with
chronic hepatitis, since it has been shown on metaregression
analysis to demonstrate a signiﬁcantly higher sensitivity
for early HCC with US every 6 months than with annual
surveillance [8, 9]. Although detailed discussion regarding
the serological markers for HCC are beyond the scope of this
paper, brief mention needs to be made with regards to AFP
since it is the single most commonly used serologic marker
for HCC.
As with all diagnostic tests, the sensitivity proﬁle of AFP
is reduced when a higher threshold is applied in order to
improve speciﬁcity. On its own, AFP is not suﬃcient as a
screening test for HCC [10]. Taking the most commonly
report cut-oﬀ of 20ng/mL, AFP carries a sensitivity of 41–
65% and a speciﬁcity of 80–94% [11]. Particularly in high-
risk patients, it has a low positive predictive value of around
25% [12].
US screening is superior to alpha-fetoprotein assay for
detection of HCC [13]. Combined AFP and US further
increases detection rate [14]. As such, combined use of
AFP monitoring and US is recommended, in patients with
chronicHCV[15,16]aswellasHBV,whereithasbeenfound
to reduce mortality (37–41%) [17, 18]. Despite the higher
sensitivity and speciﬁcity of CT and MRI for detection of
HCC[19],thesehavenotbeenvalidatedforandaretherefore
not currently recommended for screening.
4.Imaging Diagnosis
A feature common to the APASL and AASLD guidelines is
that the recommendations for imaging diagnosis of HCC
are to be interpreted in the context of patients at high-
risk for HCC [3, 4]. This would include patients with liver
cirrhosis and those with chronic HBV infection without
deﬁnite cirrhosis. It is important to make this distinction,
since the guidelines may not necessarily apply to the general
population.
4.1. Classical Imaging Features. There is little disagreement
between the consensus guidelines of the APASL and the
AASLD on the deﬁnition of imaging features of classical
HCC. The presence of arterial hypervascularity and washout
aregenerallyconsideredtobehighlyspeciﬁcforthediagnosis
of HCC, and shall henceforth be referred to as “classical
imaging features” [20]. In particular, this enables dif-
ferentiation from intrahepatic cholangiocarcinoma, which
shows delayed enhancement [21] .A tt h et i m eo ft h eE A S L
guidelines in 2001, the importance of “washout” was not
fully appreciated, hence not included. However, this is now
speciﬁcally emphasized as a crucial feature in the APASL and
AASLD guidelines.
Arterialhypervascularityisdeﬁnedasincreasedenhance-
ment of the lesion in the hepatic arterial phase of imaging
relative to the background liver. This is based on the fact that
HCC receives predominant vascular supply via the hepatic
artery. A precontrast and a dynamic postcontrast scan of the
l i v e ri sn e c e s s a r yt od e m o n s t r a t et h i so ni m a g i n g .
“Washout” of the lesion is based on the fact that HCC
contains predominantly arterial blood and so, by the time
portal venous and delayed images are acquired, the lesion is
observed to be hypoattenuating on CT (or in the case of US,
“hypoechoeic” and in the case of MRI, “hypointense”) to the
surrounding liver at the portal venous or equilibrium phase.
Washoutcanbeexplainedintermsoftracerkineticmodeling
of a lesion with high proportion of intravascular space [22]
For demonstration of washout, the delayed phase has been
shown to besuperior tothe portal venousphase, both forCT
and MRI; this is estimated at 2-3 minutes following injection
of intravenous contrast agents [23, 24]. The timing of the
scans are important, and this has led to the recommendation
that imaging be performed in specialised centers [25].
The presence of elevated AFP greater than 200ng/mL
is no longer required under the revised AASLD guidelines,
as it is recognised that there are inherent false-positives
(in cirrhotic patients) and false negatives [3, 25]. Detailed
discussion on the role of AFP is beyond the scope of this
paper, although the limitations of AFP as a serologic marker
for HCC has previously been alluded to.
Despite the abundant use of multidetector row technol-
ogy, CT may underestimate the extent of disease in around
50% of cases [26]. Although it has been established in
that MRI is superior in the detection of HCCs, particularly
the lesions smaller than 2cm in size [27, 28], neither the
APASL nor the AASLD recommends the use of MRI over
CT for staging of disease. In the study by Pitton et al. where
direct comparison between MRI and 64-row CT, MRI was
signiﬁcantly more sensitive in detecting tumour nodules
[29]. However, the decision to use MRI over CT can be
limited by its relatively high cost and technical demand.
4.2. Atypical Imaging Features—AASLD Guidelines. Most of
the diﬀerences between the AASLD and APASL guidelines
for the radiological diagnosis of HCC lie in the approach
to lesions that do not demonstrate the classical imaging
features of HCC. The AASLD essentially does not recognise
use of nonvascular imaging criteria, and in the absence of
the classical arterial hypervascularity and venous washout
pattern of HCC, further evaluation is necessary. While this
makes the AASLD guidelines more applicable to transplant
guidelines (Milan and UCSF criteria), where diagnoses were
based on vascular enhancement pattern of HCCs [30, 31], it
may also lead to understaging of disease [3].International Journal of Hepatology 3
Often, the lesions that do not conform to the classical
imaging features are better diﬀerentiated and smaller than
2cm in size. These “early” HCCs have been shown to
contain not only fewer portal tracts but also fewer arterioles
[32]. This is reﬂected by their atypical imaging appearances,
where 87% of well-diﬀerentiated lesions and 41–62% of
lesions smaller than 2cm showed either absence of arterial
hypervascularity, venous washout, or both (Figure 1)[ 33,
34]. Importantly, these are the lesions that should be the
targetofsurveillanceanddiagnoses, sincetheycanbeablated
with high likelihood of cure [25].
Conversely, for the larger lesions, even in the absence
of the classical imaging features, size alone is a risk factor
[34]. In the series by Yu et al. in patients with known HBV-
induced cirrhosis, lesions with a spherical contour greater
than 2cm were found to have high malignant potential,
despite lack of arterial hypervascularity [35]. Indeed, the
classical enhancement features for HCC in large lesions may
be confounded by the presence of central necrosis and lesion
heterogeneity (“nodule-in-nodule” appearance) [36].
In the revised AASLD guidelines, lesion size continues to
predominate, though less so compared to the earlier edition.
In the earlier AASLD guidelines, any lesion greater than
2cm in size and demonstrates classical imaging features can
be treated without biopsy. For lesions that were between 1
to 2cm in size, two imaging modalities, rather than one,
with classical features were needed to conﬁrm the presence
of HCC and avoid biopsy. This has been recently revised
such that any lesion larger than 1cm that demonstrate the
classical pattern of HCC can be deemed as such and treated
accordingly without biopsy. This is because as with the larger
lesions, the approach of using a single imaging technique for
lesions that are between 1 to 2cm yields acceptable results
[37–39].
In the presence of atypical ﬁndings from a single imaging
test (CT or MRI), the AASLD recommends a diﬀerent
imaging modality (CT or MRI) for further assessment.
This has been validated by Khalili et al. in which single
imaging scans were found to have similar speciﬁcity (91–
99%) to two coincidental positive scans (91–100%) with
much less resource utilization and higher sensitivity (74–
89% versus 53–62%) [38]. However, if atypical ﬁndings are
againdemonstrated,biopsyisrecommended.Biopsyrestores
the speciﬁcity of imaging to 100% where any of the ﬁndings
are atypical [40]. Note that contrast-enhanced ultrasound
(CEUS) is not considered to be speciﬁc enough (besides the
fact that the CEUS agents are not commercially available in
the United States) and is excluded from the revised AASLD
guidelines [3].
Even though the majority of cirrhotic nodules smaller
than 1cm are benign [3] ,K i me ta l .f o u n dt h a ti np a t i e n t s
with mild cirrhosis related to HBV, HCCs were present in
two-thirds of hypervascular lesions smaller than 1cm [41].
As such, in lesions smaller than 1cm, the speciﬁcity of
imaging for HCC is limited [42], and based on AASLD
guidelines, these cannot be regarded as HCC, regardless
of the enhancement pattern. A foreseeable problem with
imposing this size criteria is that it can pose dilemma
in clinical practice, since it has been shown that subcen-
timetre lesions can be diagnosed, particularly with MRI
[43].
Instead of aggressively chasing the diagnosis through
biopsy for lesions smaller than 1cm (which in itself can be
technically challenging due to size), close interval followup
in 3 months using the modality that best depicts the lesion
is recommended. Here, the guidelines may be debated. It
has been suggested that for among hypervascular nodules
smaller than 1cm, those smaller than 5mm, are subcapsular
in location, wedge shaped, or ill deﬁned (more likely to
represent vascular shunts) a 6-month followup is suﬃcient,
but when the nodule is round, oval, intraparenchymal, or in
a dominant mass (more suspcious for HCC), closer imaging
followup at 3-monthly intervals should be performed [44].
This may reduce unnecessary imaging but requires further
validation. Typically,nodulesare declaredbenignonlyifthey
regressorremainstablefortwoyears,sinceHCCnodulescan
grow very slowly [2].
4.3. Atypical Imaging Features—APASL Guidelines. The
APASL guidelines approach the atypical lesions in diﬀerent
manners. Essentially, these focus on Kupﬀer cell density as a
marker of benignity. It has been shown that Kupﬀercell den-
sity decreases with dediﬀerentiation of the cirrhotic nodule
[45, 46]a n di sr e ﬂ e c t e db yt w od i ﬀerent classes of imaging
contrast agents. The ﬁrst is a second generation CEUS agent
containing perﬂuorobutane microbubbles (Sonazoid, GE
Healthcare); its use is currently limited as it is not available
outside of Japan. The other is superparamagnetic iron oxide
(SPIO) MR contrast agents, namely ferucarbotran (Resovist,
Bayer) and ferumoxide (Feridex, AMAG pharmaceuticals).
S i n c en o r m a ll i v e rt i s s u ec o n t a i n sK u p ﬀer cells, which are
in turn part of the reticuloendothelial system, malignant
lesions can be reliably diﬀerentiated from nontumourous
liver based on the fact that they do not contain Kupﬀer
cells.
The APASL guidelines basically divides the atypical
lesions into those that are hypervascular (and do not
demonstrate washout) and those that are hypovascular (and
do not show arterial hypervascularity). For hypervascular
lesions that do not demonstrate washout, early HCCs can
be reliably diﬀerentiated from focal nodular hyperplasia and
arterioportal shunts based on diﬀerential uptake of Kupﬀer-
speciﬁc contrast agents. On the parenchymal phase of
imaging, HCCsshouldappearas unenhancedareas onCEUS
and as T2∗-hyperintense lesions on SPIO-enhanced MRI.
However, a foreseeable limitation is in the characterisation
ofotherhypervascularmalignancies,suchasneuroendocrine
carcinoma metastases.
The approach to the hypovascular lesion is a little more
complex, while at the same time, the diﬀerential list for this
includes a larger group of hepatic malignancies, including
intrahepaticcholangiocarcinoma andmetastases. Basically,if
the lesion is initially shown to be hypovascular on CT and
MRI, CEUS may be attempted to demonstrate enhancement
in the hepatic arterial phase. If this is shown to be true,
the lesion may be deemed HCC. Alternatively, if Kupﬀer-
speciﬁc imaging demonstrates a relative lack of uptake, the
lesion can be regarded as HCC. Again, the limitation of4 International Journal of Hepatology
(a) Axial fat-saturated respiratory triggered T2-
weighted fast spin echo image (TE 80msec)
shows a mildly hyperintense 1.2cm lesion
(arrow) in segment 4
(b) Axial contrast-enhanced fat-suppressed T1-
weighted spoiled gradient recalled echo (LAVA)
image of the liver at the same level, taken at 20
seconds following injection of standard dose of
intravenous contrast (Dotarem, Guerbet) shows
no appreciable enhancement in the expected site
of the lesion (arrow)
(c) Axial LAVA image in the delayed phase (180
seconds postinjection) shows the lesion (arrow)
as hypointense to the surrounding liver, consis-
tent with washout
(d) On the axial DW image (b = 500s/mm2),
the lesion (arrow) is hyperintense. This was
correspondingly hypointense on the ADC map
(not shown), consistent with restricted diﬀusion
Figure 1: HIV positive patient with chronic HBV infection without known liver cirrhosis. By the AASLD and APASL guidelines, this lesion
would require further evaluation. CT done prior to the MRI also failed to demonstrate arterial hypervascularity. Note, however, that the
lesion showed suspicious features on T2-weighted and DW imaging. The lesion was biopsied percutaneously under ultrasound guidance
and showed to represent a well-diﬀerentiated HCC.
such an approach is thattheother concomitanthypovascular
lesions such as adenocarcinoma metastases are not deﬁnitely
excluded.
Although CT arterial portography and CT hepatic arte-
riography (CTPA and CTHA) are considered to be signiﬁ-
cantly more sensitive for demonstrating the early vascular
changes in small HCCs [47], these are invasive and the
expertise fortheseproceduresisnotreadily availableinmany
centres around the world.
The ensuing sections will brieﬂy review various imaging
modalities used in diagnosis and assessment of HCC; some
of these are included in the current APASL guidelines, the
rest are meant to inform the reader of recent advances in
imaging of HCC that may potentially be integrated into
future diagnostic imaging algorithms.
4.4. Kupﬀer Speciﬁc Imaging: Sonazoid CEUS and SPIO
Agents. Given that the APASL recommends the use of
Kupﬀer-speciﬁc agents (Sonazoid and SPIO agents) for
lesion characterisation, a more detailed discussion on the
utility of these contrast agents needs to be made. However,
in part because neitherSonazoid nor currently commercially
a vailableSPIOagentsar eappr o v edb ytheU nit edStat esF ood
and Drug Administration (FDA) for clinical use, these are
not included under the diagnostic algorithm by the AASLD.
CEUS on its own is an accepted imaging modality for HCC
diagnosis under the APASL guidelines and this has been
validated even for lesions smaller than 2cm [37]. Jang et al.
showed that the sensitivity, speciﬁcity, and accuracy ofCEUS
for diagnosing HCC was 87%, 100%, and 93%, respectively,
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Inherently,theenhancement patternsoflesionsonCEUS
reﬂect tumour microvascular morphology, making it a valu-
able method for predicting the histological grade [49]w h i l e
providing valuable information for antiangiogenic therapy
[50]. The keys limitations of CEUS are that it is operator
dependent and has decreased sensitivity in obese patients
and lesions far from the skin surface [51]. Furthermore,
the phenomenon of “washout” on CEUS is less speciﬁc
for HCC than it is with CT or MRI, due to signiﬁcant
overlap between nearly all malignant and some benign
lesions. Washout in CT or MRI is determined by contrast
dynamics inboththeintravascularspaceandtheinterstitium
whereas CEUS washout is predominantly related to contrast
dynamics in the intravascular space (Figure 2). Moderately
diﬀerentiated HCC generally shows classic enhancement
features, while well-diﬀerentiated and poorly diﬀerentiated
tumours account for most atypical variations [52].
Adding Kupﬀer-speciﬁc phase imaging to CEUS proto-
cols may yield additional information that can be used to
further assess histologic grades of tumour and enable bet-
ter characterisation among dysplastic nodules, moderately-
diﬀerentiated and poorly diﬀerentiated HCCs [45]. As with
SPIO imaging, Kupﬀer-speciﬁc imaging enables detection
of all moderately and poorly diﬀerentiated HCCs [46]. The
reader should however bear in mind that these ﬁndings are
read in the context of patients at high-risk for HCC devel-
opment. Kupﬀer phase imaging itself remains nonspeciﬁc,
sinceevenbenignlesions,suchashaemangiomas, thatdonot
contain Kupﬀercells, will appear as hypoechoeic on Kupﬀer-
speciﬁc phase of CEUS.
Similarly, use ofSPIOhasbeenshown inmultiplestudies
toimproveaccuracyofMRIfordetectionofHCCs.However,
detailed discussion of the SPIO agents will be avoided since
these are currently out of production, except to say that
experience with SPIO agents thus far had been promising
and that it potentially improves imaging detection of HCCs
[40, 53, 54]. Combined gadolinium chelate and SPIO
MRI, termed “double contrast” MRI, is technically more
cumbersome, even though it appears to increase the tumour
to liver contrast to noise ratio, and therefore sensitivity, over
multiphasic CT [55, 56] routine Gd-enhanced MRI [57], or
SPIO-enhanced MRI [58, 59].
4.5. Imaging of TumourThrombosis in HCC: Worth a Look?
Although important for staging and treatment decision
making, assessment of portal vein thrombosis for tumour
involvement is currently not considered in both the APASL
orAASLDguidelinerecommendations. Image guidedpercu-
taneous biopsy of suspected portal vein tumour thrombosis
is feasible but invasive [60]. It may be possible to apply
the same (AASLD or APASL) criteria used in diagnosis
of HCC nodules to the vessel of interest to determine
tumour involvement, but this does not appear to have been
well studied. Separate guideline recommendations may be
necessary.
Various noninvasive techniques have been investigated,
and among them, CEUS appears to show fairly good success
[61], superior to that of CT [62]. CEUS itself carries
a sensitivity of 88% for diagnosing malignant portal vein
thrombosis [63]. Combining CEUS and CT, Sorrentino and
colleagues found 100% positive predictive value if both
imaging modalities demonstrated arterial hypervascularity
within the thrombi. In that study, the overall sensitivity of
imaging for malignant thrombosis was 75% [64]. In the
small series by Sun et al. 18-FDG PET may discriminate
between benign and malignant portal vein thrombi but
larger numbers are necessary [65]. Based on the absolute
ADC values, diﬀusion-weighted (DW) MRI shows promise
for discriminating between bland and tumour portal vein
thrombi [66], but has not been fully validated.
4.6. Hepatocyte-Speciﬁc MRI Agents, DW MRI and Positron
Emission Tomography (PET): On the Horizon?
Functional imaging of HCC is fast becoming a reality and
a brief mention of some of these techniques shall be made.
Hepatocyte-speciﬁc gadolinium chelate agents are relatively
new and are not currently included in the guideline rec-
ommendations. Gadoxetic acid (Gd-EOB-DTPA, Primovist,
Bayer) and gadopentetate dimeglumine (Gd-BOPTA, Multi-
hance, Bracco) are two such contrast agents that have been
shown to improve diagnosis of HCC, showing diagnostic
performance similar to or better than SPIO [67, 68]a n d
comparable to double contrast MRI [69].
Hepatocyte-speciﬁc gadolinium chelate agents allow for
multiphasic dynamic contrast-enhanced MR imaging to be
combined with the hepatocyte-speciﬁc phase. These require
delayed scanning of approximately 20 minutes in the case
of Gd-EOB-DTPA and 60–120mins in the case of Gd-
BOPTA to provide maximal lesion to liver contrast [70].
Speciﬁcally, they may be used to diﬀerentiate HCCsfrom the
arterial enhancing pseudolesions and are recommended for
diagnosis of focal nodular hyperplasia [71, 72]. Like SPIO
agents, they may allow for characterisation of the degree of
tumour diﬀerentiation [73].
Gd-BOPTA-enhanced MRI with hepatocyte-speciﬁc
phase imaging improves diagnosis over routine multiphasic
CT or MRI [74], with quoted sensitivity and speciﬁcity rates
of 97% and 88%, respectively, [75, 76]( Figure 3). Gd-EOB-
DTPA-enhanced MRI is also superior to CT, with reported
accuracy of 0.88, compared to 0.74 in CT [77–79]. Between
the two agents, Gd-EOB-DTPA was more sensitive than Gd-
BOPTA for HCC detection (86% compared to 64%) [80],
perhaps related to the fact that the extent of hepatobiliary
uptake is considerably less with Gd-BOPTA (5% versus
50%).
Combining Gd-EOB-DTPA-enhanced MRI and Son-
azoid CEUS detected 73% of the nodules not detectable by
multiphasicCT[81].Itmayalsobecombinedwithdiﬀusion-
weighted (DW) MRI to improve diagnosis [82]. However,
assessment for lesions smaller than 1cm can be still poor
(sensitivity of 29–43%) [83], and hence further experience
is necessary with these hepatocyte-speciﬁc agentsbefore they
are included in imaging guidelines.
DW MRI studies the random motion of water molecules
and shows promise for detection and characterisation as well6 International Journal of Hepatology
(a) Axial LAVA image in the arterial phase shows
a hypervascular lesion (arrow) in segment 5/6
(b) Axial LAVA image at 3 minute delay shows
no signiﬁcant washout in the expected location
(arrow) of the lesion. This would be deemed
atypical based on consensus criteria
(c) CEUS (SonoVue, Bracco) demonstrates avid
arterialenhancement within thelesion(arrow) at
18 seconds
(d) The lesion showed rapid washout, become
mildly hypoechoeic (arrow) to the surrounding
liver at 35 seconds,consistentwith HCC. CEUS is
not considered in the revised AASLD guidelines;
by APASL criteria, this satisﬁes criteria for HCC.
Histology conﬁrmed moderately diﬀerentiated
HCC
Figure 2: Patient with chronic HCV infection found to have a 2cm hypoechoeic nodule on surveillence ultrasound scan. Both CEUS and
multiphasic contrast-enhanced MRI were performed.
as posttreatment assessment of tumours [84]. It improves
MR detection of HCCs, particularly in lesions smaller than
2cm[85], with sensitivities of 84–98% compared to 76–85%
for multiphasic MRI alone [86–88]. Potentially, objective
measurement of the apparent diﬀusion coeﬃcient (ADC)
may allow for distinction between the diﬀerent tumour
grades [89, 90]. It can be combined with SPIO-enhanced
MRI,raising sensitivity from 66% to70%,while maintaining
high speciﬁcity of 98% [91]. DW MRI also shows potential
for assessment of treatment response to local ablative thera-
pies[88,92].Itsroleinthediagnosticalgorithmisnotcertain
at this point, although, given the promising results and its
ease of implementation in routine clinical practice (due to
fast acquisition times, no needs for additional hardware and
ease of interpretation), incorporation into future guidelines
is anticipated.
18Fluorodeoxyglucose (FDG) PET is generally accepted
to have low sensitivity (50–68%) for intrahepatic HCC
[93–95] and is therefore not considered to be useful for
diagnosis of HCC, except perhaps in cases of poorly diﬀer-
entiated HCC where it may show better results [96]. Dual
tracer imaging with the addition of 11C-acetate improves
sensitivity for intrahepatic disease from 37–49% for 18-
FDG and 11-C alone to 90% when combined [97]. The
role of 18-FDG is limited to evaluation of extrahepatic
disease [98], with sensitivity of 13–84%, depending on
the size of the lesions [99]. Newer tracers such as 18F-
choline [100]a n d 18F-thymidine [101] have shown slightly
better results, but further experience is needed. At present,
PET plays a small role in imaging assessment of HCC,
but tumour-speciﬁc tracers may be the key to its use in
future.International Journal of Hepatology 7
(a) Axial fat-saturated respiratory triggered T2-
weighted fast spin echo image (TE 80msec) does
not reveal abnormal signal focus in the left lobe,
even on retrospective review
(b) Axial LAVA image in the portal venous phase
shows a questionable focus of mixed intensity
(arrow) in segment 3. This was mainly due
to pulsation artefact from the abdominal aorta.
No enhancement was seen in the corresponding
section on hepatic arterial phase imaging (not
shown)
(c) Axial LAVA hepatocyte-speciﬁc phase image
at 20min post injection conﬁrms the presence
of a 2.2cm lesion (arrow) in the subcapsular
region of segment3.Given the size,HCC ishighly
suspected,even in the absenceof classicalimaging
features. Note partially treated lesion in the right
lobe (arrowhead)
Figure 3: Chronic HBV patient with known multifocal HCC presumed to be conﬁned to the right lobe, completed one session of TACE.
US suggested possible nodule in the left hepatic lobe, but this was occult on multiphasic CT. MRI with standard dose of Gd-EOB-DTPA was
performed.
5.Summary
Our understanding of the pathophysiology of HCC has
improved tremendously over the past decade. This has been
paralleled by advancements in US, CT and MRI technology,
along with developmentof various Kupﬀer- and hepatocyte-
speciﬁc imaging contrast agents. As the treatment of HCC
becomes more sophisticated, a greater need for highly accu-
rate diagnosis is necessary. The consensus recommendations
by the AASLD and APASL on the radiological diagnosis of
HCC underscore the push for noninvasive diagnosis of HCC
in avoidance of biopsy.
While there is general consensus with regards to the
surveillance for HCCs in high-risk patients, pertinent dif-
ferences in the recommendations for imaging diagnosis of
HCC exist. These reﬂect the diﬀerences in the availability
of diagnostic imaging resources in diﬀerent regions. For
example, Sonazoid is not available for use outside of Japan
and is therefore unique to the APASL guidelines. In a way,
they also point to diﬀerences in practice patterns and the
controversies in our understanding of “early” HCC. The
AASLD guidelines demand that the classical enhancement
features of HCC are demonstrated, accepting that this
may limit sensitivity; biopsy is regarded as a means to
restore sensitivity. On the other hand, the APASL guidelines
emphasizes theuse ofKuppferspeciﬁc imaging techniquesto
improve diagnostic performance.
With rapid and continual improvement in diagnostic
imaging modalities and validation of these guidelines,
further reﬁnements to the diagnostic algorithm can be
expected in the near future. At present few of the established
techniques have fallen out of favour; SPIO agents are on the
declineduetodecreased clinicalusage, while doublecontrast
MRI, CTHA and CTAP are cumbersome to perform and not
compatible with routine clinical practice.
Hepatocyte-speciﬁc MRI contrast agents are increasingly
used in the United States, Europe and parts of Asia, as well as
DW imaging, which is now already widely applied in routine
clinical practice, demonstrate great promise to improve
currentmethodsofimaging diagnosis.However,beforethese
can be incorporated into the imaging algorithms, validation
of their utility is necessary. Similarly, the utility of imaging
for other important aspects of HCC management, such as
for noninvasive diagnosis of portal vein tumour thrombosis,
may also need to be addressed in time to come.
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